Loading data for CAPR — first visit, this takes a few seconds.

Alert

Capricor Therapeutics Inc... (CAPR)

NasdaqGS: CAPR · Real-Time Price · USD

6.29

-0.54 (-7.91%)

At close: Aug 21, 2026, 8:00 PM

6.38

+1.42%

After-hours: 7:59 PM

The price, the headline numbers and the latest news, in one place.

-7.91% (1D)

No data available

Bid	5.02
Market Cap	365.69M
Revenue (ttm)	n/a
Net Income (ttm)	-129.42M
	0.53
	-2.45
	n/a
	-4.12
P/B (ttm)	1.48
P/S (ttm)	n/a
Earnings Date	Nov 10, 2026

Ask	7.75
Volume	8,203,336
Avg. Volume (20D)	4,955,670
Open	6.80
Previous Close	6.83
Day's Range	6.01 - 7.08
52-Week Range	2.96 - 40.37
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome prot...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 13, 2007

Employees 231

Stock Exchange NasdaqGS

Ticker Symbol CAPR

Website https://www.capricor.com

Full Company Profile

Financial Performance

In 2025, Capricor Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 22.27M. Earnings were -105.04M, an increase of 159.58%.

Financial Statements

Earnings Surprise

Capricor Therapeutics has released their quarterly earnings on Aug 13, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.7 misses estimates by -0.12, with -32.08% YoY decline.

Next Earnings Release

Capricor Therapeutics Inc. is scheduled to release its earnings on Nov 10, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

1 day ago · Stocktwits

CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel

The U.S. Food and Drug Administration’s target action date for Capricor’s biologics license application for Deramiocel is Saturday.

1 day ago · Stocktwits

Capricor Draws Investor Attention As Shareholder Kaos Capital Pushes For Board Shakeup Ahead Of Key FDA Decision On DMD Therapy

In a letter to Capricor’s shareholders, Kaos said it intends to nominate two independent directors and to have the company establish a board-led M&A and Strategic Alternatives Committee.

1 day ago · BioPharma Dive

Shareholder pressures Capricor; Lilly dives deeper into vaccines

Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.

2 days ago · Motley Fool

Capricor (CAPR) Q2 2026 Earnings Call Transcript

Deramiocel faces regulatory headwinds; management pursues upper limb indication.

2 days ago · Insider Monkey

Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) closed 58% higher at $6.65 on August 14 after the company said the FDA was willing to review an amendment containing 24-month data for deramiocel, its Duchenn...

Page 1 of 2

Capricor Therapeutics Inc... (CAPR)